Kinetics of the Finasteride Prostate Induced Apoptosis
This trial is active, not recruiting.
|Condition||benign prostatic hyperplasia|
|Sponsor||Hospices Civils de Lyon|
|Start date||December 2004|
|Trial size||90 participants|
|Trial identifier||NCT00130767, 2003.316|
The aim of this study is to evaluate the mechanisms involved in the apoptosis induced by a treatment of finasteride on benign prostate hyperplasia (BPH). Five sets of patients who need a surgical procedure because of low tract urinary symptoms are randomly attributed to one of five sets of treatment: 0, 7, 14, 21 or 28 days of finasteride treatment before the day of the procedure. Prostate histological fragments are conditioned for molecular and histologic studies.
|Intervention model||parallel assignment|
Date of the maximum apoptosis in the prostate tissues treated by finasteride
Molecular mechanisms involved in BPH finasteride induced apoptosis
Decrease in the frequency of the hemorrhagic incidents after the surgical procedure in patients with a treatment using finasteride
Male participants from 40 years up to 90 years old.
Inclusion Criteria: - Patients with low tract urinary symptoms needing a surgical procedure - No previous treatment with finasteride - No androgen deficiency; no prostate cancer suspected.
|Official title||Kinetics of the Finasteride Prostate Induced Apoptosis|
|Principal investigator||Alain RUFFION, MD|
Call for more information